Comparison criteria

This page is a variable. The page identifier is Op_en6356
Moderator:Nobody (see all) Click here to sign up.
Give your opinion to the peer rating of the content of this page. {{ #opasnet_rater: }}
Upload data

Progression class

In Opasnet many pages being worked on and are in different classes of progression. Thus the information on those pages should be regarded with consideration. The progression class of this page has been assessed: This page is a draft The relevat content and structure of the page is already present, but there still is a lot of missing content.

This page needs a curator. Learn more about curating Opasnet pages.

Question

Which comparison criteria should be used in the tendering process for the selection of a pneumococcal conjugate vaccine to be included in the national vaccination programme for children in Finland? The tendering process will be initiated during the autumn of 2014.

• Possible comparison criteria include price, benefits, safety and technical properties.
  • Price refers to the bargaining price of the vaccine.
  • Benefits refer to the decrease in disease burden caused by large scale use of the vaccine. As a result health care costs decrease and the quality of life attributed to improved health increases.
  • Safety
  • Technical properties
• The benefits of the pneumococcal conjugate vaccine are quantified by the decrease of disease caused by pneumococcus and Haemophilus influenzae -bacteria.
• The benefits are assessed in the entire Finnish population.

Answer

The tentative proposal is that the comparison is based on price and assessed benefits. Benefits are quantified as the expected decrease in invasive pneumococcal disease incidence due to vaccination. This tentative proposal is the basis for the conversation beginning in the summer of 2014.

Rationale

According to the public procurement law, comparison criteria related to differences in the products can be applied if (1) the differences are clearly demonstrated and (2) the differences can be quantified in terms of increased or decreased benefits. In particular, technical differences typically fall outside of this realm. So far no credible differences in safety among the currently licensed pneumococcal conjugate vaccines have been demonstrated.

Comment the content

Current comments that have not yet been included in the main page or talk page.

You can give comments about the content without login simply by writing your comments into the text box below. The page moderator will include your comments in the actual content of the page and then moves the comment to the archive:

Your comment about the page content or discussion: To what part of the page does you comment refer?:

Comments to be removed (after they have been moved to the page text)

ID of the comment to be removed: Reason to remove: - Select - Comment has been included in a discussion or text on the page Comment is not relevant on this page Comment is vandalism (use sparingly)